Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels

Biophysical Journal

Volumn 97, Issue 9, 2009, Pages 2379-2387

  Lai, Bonnie E ^a   Henderson, Marcus H ^a   Peters, Jennifer J ^a   Walmer, David K ^b   Katz, David F ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE;

ARTICLE; DIFFUSION; DOSE TIME EFFECT RELATION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; OUTCOME ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SPERM; VIRION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 72249098848     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2009.08.010     Document Type: Article

References (56)

1. Rosario, M. C., P. Jacqmin, P. Dorr, E. van der Ryst, and C. Hitchcock. 2005. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity ofmaraviroc. Clin. Pharmacol. Ther. 78:508-519.
2. Rosario, M. C., B. Poland, J. Sullivan, M. Westby, and E. van der Ryst. 2006. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J. Acquir. Immune Defic. Syndr. 42:183-191.
3. Davenport, M. P., R. M. Ribeiro, L. Zhang, D. P. Wilson, and A. S. Perelson. 2007. Understanding the mechanisms and limitations of immune control of HIV. Immunol. Rev. 216:164-175.
4. Perelson, A. S. 2002. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2:28-36.
5. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1582-1586.
6. McGowan, I. 2006. Microbicides: a new frontier in HIV prevention. Biologicals. 34:241-255. (Pubitemid 44750691)
7. Balzarini, J., and L. Van Damme. 2007. Microbicide drug candidates to prevent HIV infection. Lancet. 369:787-797. (Pubitemid 46335821)
8. Cutler, B., and J. Justman. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8:685-697.
9. Johnston, M. I., and A. S. Fauci. 2007. An HIV vaccine-evolving concepts. N. Engl. J. Med. 356:2073-2081.
10. Padian, N. S., A. Buve, J. Balkus, D. Serwadda, and W. Cates. 2008. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 372:585-599.
11. Honey, K. 2007. Microbicide trial screeches to a halt. J. Clin. Invest. 117:1116.
12. Skoler-Karpoff, S., G. Ramjee, K. Ahmed, L. Altini, M. G. Plagianos, et al. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 372:1977-1987.
13. Tao, W., C. Richards, and D. Hamer. 2008. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses. 24:925-929.
14. Karim, S. A. 2009. Safety and effectiveness of vaginal microbicides buffer gel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. Proc. 16th Conf. Retroviruses Opportun. Infect.
15. Klasse, P. J., R. Shattock, and J. P. Moore. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59:455-471.
16. Tuckwell, H. C., P. D. Shipman, and A. S. Perelson. 2008. The probability of HIV infection in a new host and its reduction with microbicides. Math. Biosci. 214:81-86.
17. Chakraborty, H., P.K. Sen, R.W.Helms, P. L.Vernazza, S.A. Fiscus, et al. 2001. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 15:621-627. (Pubitemid 32281358)
18. Geonnotti, A. R., and D. F. Katz. 2006. Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. Biophys. J. 91:2121-2130.
19. Geonnotti, A., P. Kiser, M. Rosen, K. Barnhart, and D. Katz. 2008. Three-dimensional pharmacokinetic modeling of microbicide delivery by intravaginal rings within an MRI-derived finite-element vaginal compartment. Microbicides Meeting. New Delhi, India.
20. Rohan, L. C., and A. B. Sassi. 2009. Vaginal drug delivery systems for HIV prevention. AAPS J. 11:78-87.
21. Justin-Temu, M., F. Damian, R. Kinget, and G. Van Den Mooter. 2004. Intravaginal gels as drug delivery systems. J. Womens Health (Larchmt). 13:834-844. (Pubitemid 39369265)
22. Mauck, C. K., D. F. Katz, E. P. Sandefer, M. D. Nasution, M. Henderson, et al. 2008. Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception. 77:195-204.
23. Henderson, M. H., G. M. Couchman, D. K. Walmer, J. J. Peters, D. H. Owen, et al. 2007. Optical imaging and analysis of human vaginal coating by drug delivery gels. Contraception. 75:142-151.
24. Henderson, M. H., J. J. Peters, D. K. Walmer, G. M. Couchman, and D. F. Katz. 2005. Optical instrument for measurement of vaginal coating thickness by drug delivery formulations. Rev. Sci. Instrum. 76:034302.
25. Reference deleted in proof.
26. Barnhart, K., E. S. Pretorius, and D. Malamud. 2004. Lesson learned and dispelled myths: Three-dimensional imaging of the human vagina. Fertil. Steril. 81:1383-1384.
27. Greenhead, P., P.Hayes, P. S.Watts, K. G. Laing,G. E. Griffin, et al. 2000. Parameters of humanimmunodeficiency virus infection of humancervical tissue and inhibition by vaginal virucides. J. Virol. 74:5577-5586. (Pubitemid 30346592)
28. Broliden, K., A. T. Haase, S. K. Ahuja, G. M. Shearer, and J. Andersson. 2009. Introduction: Back to basics: mucosal immunity and novel HIV vaccine concepts. J. Intern. Med. 265:5-17.
29. Truskey, G. A., F. Yuan, and D. F. Katz. 2009. Transport Phenomena in Biological Systems. Pearson Education, Upper Saddle River, NJ.
30. Briggs, J. A., K. Grunewald, B. Glass, F. Forster, H. G. Krausslich, et al. 2006. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure. 14:15-20.
31. Owen, D. H., and D. F. Katz. 2005. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J. Androl. 26:459-469. (Pubitemid 40847857)
32. Boukari, H., B. Brichacek, L. Margolis, and R. Nossal. 2009. HIV-virions appear to be trapped by human cervical mucus. Biophys. J., 96:35a (Abstr.).
33. Lai, S. K., D. E. O'Hanlon, S. Harrold, S. T. Man, Y. Y. Wang, et al. 2007. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA. 104:1482-1487.
34. Geonnotti, A. R., M. J. Furlow, T. Wu, M. G. DeSoto, M. H. Henderson, et al. 2008. Measuring macrodiffusion coefficients in microbicide hydrogels via postphotoactivation scanning. Biomacromolecules. 9:748-751.
35. Coggins, C., K. Blanchard, F. Alvarez, V. Brache, E. Weisberg, et al. 2000. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76:480-483.
36. El-Sadr, W. M., K. H. Mayer, L. Maslankowski, C. Hoesley, J. Justman, et al. 2006. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 20:1109-1116. (Pubitemid 43786098)
37. Kilmarx, P. H., J. van de Wijgert, S. Chaikummao, H. E. Jones, K. Limpakarnjanarat, et al. 2006. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J. Acquir. Immune Defic. Syndr. 43:327-334.
38. Low-Beer, N., R. Gabe, S. McCormack, V. S. Kitchen, C. J. Lacey, et al. 2002. Dextrin sulfate as a vaginal microbicide: randomized, doubleblind, placebo-controlled trial including healthy female volunteers and their male partners. J. Acquir. Immune Defic. Syndr. 31:391-398.
39. Pendergrass, P. B., M. W. Belovicz, and C. A. Reeves. 2003. Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol. Obstet. Invest. 55:110-113.
40. Barnhart, K., A. Izquierdo, E. S. Pretorius, and D. M. Shera. 2006. Baseline dimensions of the human vagina. Hum. Reprod. 21:1618-1622.
41. Coombs, R. W., P. Reichelderfer, and A. L. Landay. 2003. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 17:455-480.
42. Cohen, M. S., C. Gay, A. D. Kashuba, S. Blower, and L. A. Paxton. 2007. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146:591-601.
43. Cohen, M. S., and C. D. Pilcher. 2005. Amplified HIV transmission and new approaches to HIV prevention. J. Infect. Dis. 191:1391-1393.
44. Stekler, J., B. Sycks, S. Holte, J. Maenza, C. Stevens, et al. 2008. HIV dynamics in seminal plasma during primary HIV infection. AIDS Res. Hum. Retroviruses. 24:1269-1274.
45. Galvin, S. R., and M. S. Cohen. 2004. The role of sexually transmitted diseases in HIV transmission. Nat. Rev. Microbiol. 2:33-42.
46. Klasse, P. J., R. J. Shattock, and J. P. Moore. 2006. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med. 3:e351.
47. Kieweg, S. L., A. R. Geonnotti, and D. F. Katz. 2004. Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis. J. Pharm. Sci. 93:2941-2952.
48. Kieweg, S. L., and D. F. Katz. 2006. Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery. J. Biomech. Eng. 128:540-553.
49. Kieweg, S. L., and D. F. Katz. 2007. Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing. J. Pharm. Sci. 96:835-850.
50. Lai, B. E., Y. Q. Xie, M. L. Lavine, A. J. Szeri, and D. H. Owen. 2007. Dilution of microbicide gels with vaginal fluid and semen simulants: Effect on rheological properties and coating flow. J. Pharm. Sci. 97:1030-1038.
51. Szeri, A., S. Park, S. Verguet, A. Weiss, and D. Katz. 2008. A model of transluminal flow of an anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. Phys. Fluids. 20:083101.
52. Pretorius, E. S., K. Barnhart, K. Timbers, and D. Malamud. 2002. Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception. 66:443-451.
53. Amsden, B. 2002. Modeling solute diffusion in aqueous polymer solutions. Polymer (Guildf.). 43:1623-1630. (Pubitemid 34183736)
54. Sattentau, Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 6:815-826.
55. Willits, R. K., and W. M. Saltzman. 2004. The effect of synthetic polymers on the migration of monocytes through human cervical mucus. Biomaterials. 25:4563-4571.
56. Alliance for Microbicide Development. 2009. July 2009 Pipeline Update. Silver Spring, MD.